Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L34 pseudogene 3 (RPL34P3) is classified as a pseudogene in the human genome and is not believed to encode a functional protein product[3][6]. It is derived from the parent gene RPL34, which encodes a structural component of the 60S large ribosomal subunit involved in protein synthesis, but RPL34P3 itself does not have coding capability and has no known functional role in ribosome function or disease processes[3][1][4]. There are numerous similar processed pseudogenes for ribosomal protein genes throughout the human genome, thought to originate from retrotransposition events[4]. RPL34P3 is catalogued for genomic and evolutionary studies and has no known interaction with drugs, biomarker value, or disease relevance[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L34 pseudogene 3 (RPL34P3).